# Collaborate with C-Further

## Expression of interest (EOI) form

**Please email your completed form to** **EOI@c-further.org****.** Rolling review rounds are expected to close every 6 months, please check the [website](https://www.c-further.org/work-with-us/researchers/expressions-of-interest) for the next deadline.

You can find more information about the scope and eligibility of the call, including answers to FAQs, on our website [here](https://www.c-further.org/work-with-us/researchers/expressions-of-interest). We encourage you to watch our webinar (view more information on our [website](https://www.c-further.org/event/researcher-webinar-how-to-apply-for-support)) and get in touch with the team at EOI@c-further.org to discuss your project before submitting your EOI.

Proposals will be selected in a three-stage process. The first stage is based on information provided in this form, which should be completed by the Lead Applicant. Applicants who are successful at this stage will then be invited to work with the C-Further team to submit a more detailed project proposal for review. This will require sharing of detailed data pertaining to the target/asset and a confidential disclosure agreement will be facilitated at that point. The final stage will involve detailed development of the project plan in collaboration with C-Further drug discovery scientists.

Your EOI will be seen by the team processing applications at C-Further who are under a duty of confidentiality regarding information disclosed to them during the application process. However, we advise you to not share commercially sensitive information such as structures or sequences at this stage. We advise speaking to your local Technology Transfer Office, or equivalent, about the content you wish to submit and getting in touch with us in advance if you are not able to provide sufficient non-confidential information for review. All data will be processed in line with UK data protection laws.

## Document Template Version

|  |  |  |
| --- | --- | --- |
| Document Title  | Version | Effective Date |
| C-Further\_EOI\_Template\_v1.0.docx | 1.0 | 30/09/2024 |
| C-Further\_Expressions\_of\_Interest\_form.docx. | 1.1 |  17/12/2024 |
| C-Further\_Expressions\_of\_Interest\_form.docx. | 1.2 | 24/07/2025 |

## Declaration:

By submitting this expression of interest (EOI) to C-Further, I hereby confirm that

[ ]  I have read and agree to the [EOI terms and conditions.](https://www.c-further.org/work-with-us/researchers/expressions-of-interest/EOI-terms-and-conditions)

[ ]  I have read the Frequently Asked Questions [section](https://www.c-further.org/work-with-us/researchers) of our Researcher Page which describes key principles of our collaborative research model, funding and IP management.

[ ]  I am not aware of any relevant information that has been withheld or of any information given in the application that is misleading.

[ ]  I am aware that if my expression of interest is progressed to the next stage, Cancer Research Horizons and LifeArc will need to undertake detailed diligence of the proposed project. I understand that it will be necessary to enter into a confidential disclosure agreement to enable sharing information for this purpose.

[ ]  I am aware that any research funding will be subject to Terms and Conditions that apply at the time of award and any subsequent amendments to them. If I am unable to comply, the funding may be forfeited.

### Section 1: Investigator(s)

|  |
| --- |
| **Lead Applicant** |
| **Name**Full title, all initials and surname |  |
| **Institution** |  |
| **Position** |  |
| **Address** |  |
| **Emails** |  |
| **Technology Transfer Office contact (or equivalent for SMEs)** |  |
| **Name**Full title, all initials and surname |  |
| **Position** |  |
| **Email** |  |

|  |
| --- |
| **Co-applicant 1** |
| **Name**Full title, all initials and surname |  |
| **Institution** |  |
| **Position** |  |
| **Address** |  |
| **Email** |  |
| **Technology Transfer Office contact (or equivalent for SMEs)** |  |
| **Name**Full title, all initials and surname |  |
| **Position** |  |
| **Email** |  |

|  |
| --- |
| **Co-applicant 2 (please duplicate boxes for any further coapplicants)** |
| **Name**Full title, all initials and surname |  |
| **Institution** |  |
| **Position** |  |
| **Address** |  |
| **Email** |  |
| **Technology Transfer Office contact (or equivalent for SMEs)** |  |
| **Name**Full title, all initials and surname |  |
| **Position** |  |
| **Email** |  |

### Section 2: Therapeutic Opportunity

|  |  |
| --- | --- |
| **Primary indication** Include molecularly defined subtypes wherever possible |  |
| **Other indication(s)**Other relevant indications (childhood and/or adult) |  |
| **Target**Target name, Gene, Aliases |  |
| **Intended Therapeutic Modality if known**e.g. small molecule, antibody, ADC, CAR-T etc |  |
| **Project Stage** What stage of development is your therapeutic? Please select which of the following stages applies to your project. Please select ‘other’ if your asset does not fall into any of those stages and specify which stage it is at. | [ ]  Target validation[ ]  Hit identification[ ]  Hit-to-Lead[ ]  Lead optimisation[ ]  Other – please specify:  |

### Section 3: Scientific Background

|  |
| --- |
| **Scientific Rationale** Please provide a brief summary of the clinical need this therapeutic will address and the therapeutic rationale for the target in the given indication. Aspects to cover include, but not limited to:* Disease association – evidence that mutation, altered function or altered expression of your target is correlated with, or causative of, the cancer is key (e.g. overexpression or mutation in patient samples)
* Role of the target (if biologically relevant to the proposed modality/asset) – what is the functional role of the target in cancer/normal biology. How does this inform on:
	+ Rationale for the choice of modality and/or mechanism of target disruption.
	+ Side-effect potential – such as the expression profile of the target, or any phenotypes of mouse knock-outs of the target.
* How would this fit into the care pathway e.g. would patients be stratified for your proposed treatment based on a molecularly defined subtype of the indication?

**Max 500 words.** |
|  |
| **Key target and asset validation data**Please include up to 4 key figures demonstrating target validation/asset activity.We like to see data showing that modulation of your target achieves the desired therapeutic effect in disease-relevant models. For example, it will be important to show that inhibition or activation of your target (e.g. by transgenic knockout/ overexpression, siRNA, peptides, or tool compounds) or elimination of your target cells results in the relevant phenotype. If you already have a cell ready asset, key data demonstrating its efficacy in cell or in vivo models should be provided.**No commercially sensitive structures or sequences should be shared at this stage**.**Max 2 pages.** |
|  |
| **Project development to date**Please briefly describe the project development to date and any assets in discovery, including information about their stage of development. Where appropriate, please describe how assets were identified and characterised. Indicate what you believe are the key next steps toward development of a therapeutic.**No commercially sensitive structures or sequences should be shared at this stage.** **Max 500 words.** |
|  |
| **Key References**Please include up to 5 key references to support your rationale and validation. |
|  |

### Section 4: Intellectual Property and Competitive Landscape

|  |
| --- |
| **IP and Freedom to Operate**We recommend speaking with your TTO or business development lead, reviewing our T&Cs and FAQ sections of our website before submitting the EOI. Please note some key terms:* Pre-existing (background) IP will remain with the originating parties and IP arising during the project will vest in the consortium (specifically in either Cancer Research Horizons or LifeArc).
* C-Further will have the exclusive commercial right to develop the full IP package associated with a project.
* Collaborating institutions will be granted a non-commercial research use licence to IP generated by the institution as part of a consortium project
* If we decide not to continue a project and cannot find another partner who is able to take the project to the next stage of development in our place, then we will hand the project, and all requisite intellectual property generated as part of the project back to the originator institute
 |
| Do you have freedom to operate, or does your project require access to any background IP (including know-how, materials or technologies)? **Max 100 words.** |
|  |
| Do you hold any IP related to this project? Please provide patent publication numbers where available.**Max 100 words.** |
|  |
| **Competition**Please briefly describe if there are any other therapeutic approaches in development against your target of interest and their stage of development. Please comment on how your approach is differentiated from those as well as from any others targeted at your primary patient group.**Max 200 words.** |
|  |

### Section 5: Project delivery

|  |
| --- |
| **Expertise**Please briefly describe the specific expertise you and your team have that is relevant to the progression of this project.**Max 200 words.** |
|   |
| **Resources**Please briefly describe the resources relevant to the progression of this project that are already available at your institution or through pre-existing collaborators. For example, recombinant protein for biochemical assays, cell lines, disease models, patient tissue. If required, do you have assays that could be used in high-throughput screening? **Max 200 words.** |
|  |
| **What do you expect from a collaboration with C-Further?** Note that unlike typical grant funding, we offer a truly collaborative approach to project development and delivery. Successful applicants will benefit from the drug discovery expertise and capabilities within C-Further to collaboratively develop and deliver milestone and stage-gated projects. Our drug discovery scientists will work with you to identify the key risks and gaps and their mitigation from the outset. Before submission, we would encourage applicants to view our website, watch our webinar and/or speak to us to understand how we could work with you.**Max 200 words** |
|  |

### Section 6: How did you hear about this call?

|  |  |
| --- | --- |
| **Let us know where you learned about this opportunity.** e.g. social media post, newsletter, colleagues. |  |